Elan sells Botox rival Myobloc to Solstice

- Last updated on GMT

Related tags: Botulinum toxin

Irish neuroscience based biopharmaceuticals company Elan has sold
its botulinum toxin type B product Myobloc/Neurobloc to Solstice
Neurosciences for up to €15 million.

Elan​ has announced the sale of its worldwide rights to Myobloc/Neurobloc, a botulinum toxin type B to Solstice Neurosciences, a newly formed company focused on the development, manufacturing, sales and marketing of speciality biopharmaceutical products.

Included in the sale are the related intellectual property, the product inventory, and the manufacturing facility. The associated manufacturing employees will be offered the opportunity to continue their work with Myobloc as employees of Solstice.

Myobloc was developed by Elan and is currently approved in the US, Canada and Europe for the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain.

Perhaps the most commonly known use of botulinum toxin is as an anti-wrinkle treatment. However, Myobloc has faced stiff competition from established rival Botox.

Related topics: Business & Financial, Skin Care

Related news

Related products

show more

New Vegetable Alternative to Animal Collagen!

New Vegetable Alternative to Animal Collagen!

TRI-K Industries Inc. | 07-Aug-2020 | Data Sheet

CollaPlant Z NPNF® has undergone extensive in-vivo clinical studies and sensory tests that show immediate and long-term increased skin moisturization,...

Multifunctionals for modern product protection

Multifunctionals for modern product protection

Symrise | 15-Jul-2020 | Technical / White Paper

The ‘clean’ movement is more and more of interest to consumers looking for enjoyable but responsible experience. Multifunctionals have a key role to play...

Related suppliers

Follow us

Products

View more

Webinars